Increased Serum Pentraxin 3 in Patients with Systemic Sclerosis

2009 ◽  
Vol 36 (5) ◽  
pp. 976-983 ◽  
Author(s):  
YOHEI IWATA ◽  
AYUMI YOSHIZAKI ◽  
FUMIHIDE OGAWA ◽  
KAZUHIRO KOMURA ◽  
TOSHIHIDE HARA ◽  
...  

Objective.To determine serum concentrations of pentraxin 3 (PTX3) and its clinical associations in patients with systemic sclerosis (SSc).Methods.Serum PTX3 levels from 45 patients with diffuse cutaneous SSc (dSSc), 46 with limited cutaneous SSc (lSSc), and 20 healthy controls were examined by ELISA. PTX3 expression in the sclerotic skin from SSc patients was evaluated immunohistochemically. Normal and SSc fibroblasts were cultured and PTX3 levels in the culture medium were also examined by ELISA.Results.Serum PTX3 levels were elevated in patients with SSc relative to controls. PTX3 levels in dSSc patients were significantly higher than in controls and lSSc patients. PTX3 expression in the sclerotic skin from SSc patients was more intense relative to normal skin. Elevation of serum PTX3 levels was associated with more frequent presence of pulmonary fibrosis, cardiac disease, and pitting scar/ulcer and increased serum immunoglobulin levels and erythrocyte sedimentation rates. PTX3 levels correlated positively with modified Rodnan total skin thickness score, and negatively with percentage vital capacity and percentage DLCO in patients with SSc. PTX3 levels also correlated positively with serum levels of 8-isoprostane, a marker of oxidative stress, and hyaluronan, recently identified as an endogenous ligand for Toll-like receptors. PTX3 production from cultured SSc fibroblasts was increased by stimulation with hyaluronan.ConclusionThese results suggest that elevated serum PTX3 levels are associated with the disease severity of SSc.

2009 ◽  
pp. 168-176 ◽  
Author(s):  
Akira Tokumura ◽  
Laura D. Carbone ◽  
Yasuko Yoshioka ◽  
Junichi Morishige ◽  
Masaki Kikuchi ◽  
...  

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 18019-18019 ◽  
Author(s):  
H. Schmidt ◽  
A. Roslind ◽  
J. S. Johansen ◽  
D. L. Nielsen ◽  
P. A. Price ◽  
...  

18019 Background: Elevated serum levels of the protein YKL-40 are associated with a poor prognosis in several solid tumors including melanoma (H. Schmidt, JCO 2006, Cancer 2006 in press). YKL-40 is secreted by cancer cells, macrophages and neutrophils. The function of YKL-40 is only poorly understood. It may be a growth or differentiation factor, play a role in angiogenesis or protect against apoptosis. The aim was to describe the tissue expression of YKL-40 in naevocellular naevi, carcinomas and melanomas of the skin by immunohistochemistry. Methods: Paraffin-embedded tissue sections from 40 patients with different naevocellular naevi, carcinomas and melanomas of the skin were developed with EnVision+ System-HRP K4007 (DakoCytomation) using a monoclonal antibody against YKL-40. The intensity of YKL-40 staining was scored using a semi-quantitative method. Results: YKL-40 protein expression appeared as a cytoplasmic, granular staining with no staining of membranes, nuclei or extracellular matrix. In normal skin the basal epithelial layer stained weakly positive. Melanocytes and melanophages stained negative. Macrophages and leucocytes stained positive. Hair follicles, sebaceous glands and sweat glands stained positive. Three basal cell carcinomas all stained positive. In 10 squamous cell carcinomas, the epidermal components stained positive and the invasive tumor islands were negative. In 3 keratoacanthomas, the epithelial components as well as the infiltrative tumor islands stained positive. In naevi (2 junctional, 5 compound and 1 intradermal) the epithelial components stained positive, the intradermal components stained negative. In melanomas the tumor cells stained positive in 9 of 10 specimens. Both the epidermal and the invasive components of melanomas stained positive. Three melanoma metastases all stained positive. Conclusions: YKL-40 is expressed in normal skin and in benign and malignant lesions of the skin. Generally, YKL-40 expression is increased in cells of high activity, although the invasive tumor islands of squamous cell carcinomas stain negative. In melanomas, the tumor cells may be a source of the elevated YKL-40 serum levels observed in these patients. No significant financial relationships to disclose.


2016 ◽  
Vol 77 (2) ◽  
pp. 151-159 ◽  
Author(s):  
Y.-J. Zhang ◽  
Q. Zhang ◽  
G.-J. Yang ◽  
J.-H. Tao ◽  
G.-C. Wu ◽  
...  

2009 ◽  
Vol 36 (8) ◽  
pp. 1657-1662 ◽  
Author(s):  
KOICHI YANABA ◽  
AYUMI YOSHIZAKI ◽  
EIJI MUROI ◽  
TOSHIHIDE HARA ◽  
FUMIHIDE OGAWA ◽  
...  

Objective.To determine serum levels of tumor necrosis factor-related weak inducer of apoptosis (TWEAK) and its clinical associations in patients with systemic sclerosis (SSc).Methods.Serum TWEAK levels from 70 patients with SSc were examined by ELISA. In a retrospective longitudinal study, sera from 23 patients with SSc were analyzed (followup 0.8–7.2 yrs).Results.Serum TWEAK levels were elevated in patients with SSc (n = 70) compared with healthy controls (n = 31) and patients with systemic lupus erythematosus (n = 22). Among patients with SSc, there were no differences in serum TWEAK levels between limited cutaneous SSc and diffuse cutaneous SSc. Patients with SSc who had elevated TWEAK levels less often had pulmonary fibrosis and decreased vital capacity than those with normal TWEAK levels. In the longitudinal study, SSc patients with inactive pulmonary fibrosis or without pulmonary fibrosis consistently exhibited increased TWEAK levels, while those with active pulmonary fibrosis showed decreased TWEAK levels during the followup period.Conclusion.TWEAK levels were increased in patients with SSc, and associated with a lower frequency of pulmonary fibrosis in patients with SSc. TWEAK could be a protective factor against the development of pulmonary fibrosis in this disease and as such would be a possible therapeutic target.


2021 ◽  
Vol 10 (2) ◽  
pp. 280
Author(s):  
Hirohito Kotani ◽  
Ayumi Yoshizaki ◽  
Kazuki M. Matsuda ◽  
Yuta Norimatsu ◽  
Ai Kuzumi ◽  
...  

Systemic sclerosis (SSc) is a connective tissue disease characterized by tissue fibrosis and vasculopathy in various organs with a background of inflammation initiated by autoimmune abnormalities. Calponin 3 plays a role in the cell motility and contractibility of fibroblasts during wound healing in the skin. We aimed to evaluate serum calponin 3 levels in SSc patients and their association with clinical manifestations of SSc. Serum samples were collected from 68 patients with SSc and 20 healthy controls. Serum calponin 3 levels were examined using enzyme-linked immunosorbent assay kits, and their association with clinical features of SSc was statistically analyzed. The upper limit of the 95% confidence interval of serum calponin 3 levels in healthy controls was utilized as the cut-off value when dividing SSc patients into the elevated and normal groups. Serum calponin 3 levels were significantly higher in SSc patients than in healthy controls (mean (95% confidence interval), 15.38 (14.66–16.11) vs. 13.56 (12.75–14.38) ng/mL, p < 0.05). The modified Rodnan total skin thickness score was significantly higher in the elevated serum calponin 3 level group than in the normal level group (median (25–75th percentiles), 10.0 (2.0–16.0) vs. 6.5 (3.25–8.75), p < 0.05). Moreover, SSc patients with increased serum calponin 3 levels also had a higher frequency of arthralgia (40% vs. 9%, p < 0.05). Elevated serum calponin 3 levels were associated with skin sclerosis and arthralgia in SSc patients. Serum calponin 3 levels might be a biomarker that reflects the severity of skin sclerosis and joint involvement in SSc.


2019 ◽  
Author(s):  
ANDERSON RODRIGUES DE ALMEIDA ◽  
ANDRÉA TAVARES DANTAS ◽  
MARIA EDUARDA DE OLIVEIRA GONÇALVES ◽  
MICHELLY CRISTINY PEREIRA ◽  
RAFAELA SILVA GUIMARÃES GONÇALVES ◽  
...  

2009 ◽  
Vol 36 (1) ◽  
pp. 99-105 ◽  
Author(s):  
TOSHIHIDE HARA ◽  
FUMIHIDE OGAWA ◽  
KOICHI YANABA ◽  
YOHEI IWATA ◽  
EIJI MUROI ◽  
...  

ObjectiveTo determine the serum concentrations and clinical association of polymorphonuclear neutrophilic leukocyte (PMN) elastase in patients with systemic sclerosis (SSc).MethodsSerum PMN elastase levels from 21 patients with limited cutaneous SSc (lSSc) and 32 with diffuse cutaneous SSc (dSSc) were examined by ELISA.ResultsSerum PMN elastase levels were elevated in patients with SSc, especially dSSc, compared to healthy controls. SSc patients with elevated serum PMN elastase levels had more frequent presence of pulmonary fibrosis, arthritis, contracture of phalanges, and diffuse pigmentation. Anticentromere antibody was detected less frequently in SSc patients with elevated serum PMN elastase levels than in controls. Consistently, serum PMN elastase levels also correlated positively with serum levels of KL-6 and surfactant protein-D, serological markers for pulmonary fibrosis. Serum PMN elastase levels were also associated with levels of serum 8-isoprostane, an oxidative stress marker in SSc.ConclusionSerum PMN elastase levels were elevated in patients with SSc, and it was more prominent in patients with pulmonary fibrosis, suggesting that serum PMN elastase is a novel serological marker for SSc-related pulmonary fibrosis.


2019 ◽  
Vol 312 (6) ◽  
pp. 453-458
Author(s):  
Anna Stochmal ◽  
Joanna Czuwara ◽  
Michał Zaremba ◽  
Lidia Rudnicka

Abstract Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by progressive fibrosis, vascular impairment and immune abnormalities. In recent years, adipokines (mediators synthetized by adipose tissue) have been indicated as a possible missing link in the pathogenesis of SSc. The aim of this study was to investigate the serum concentration of metabolic adipose tissue factors: adiponectin, resistin, leptin and endothelial proteins: endothelin-1, fractalkine and galectin-3 in patients with systemic sclerosis. The study included 100 patients with confirmed SSc diagnosis and 20 healthy individuals. The concentration of respective proteins was determined by enzyme-linked immunosorbent assay. The following markers showed statistically significant increased mean concentrations in patients with SSc in comparison to healthy control: resistin (13.41 vs 8.54 ng/mL; P = 0.0012), endothelin-1 (1.99 vs 1.31 pg/mL; P = 0.0072) and fractalkine (2.93 vs 1.68 ng/mL; P = 0.0007). Elevated serum levels of galectin-3 (4.54 vs 3.26 ng/mL; P = 0.0672) and leptin (19,542 vs 14,210 pg/mL; P = 0.1817) were observed. Decreased concentration of adiponectin was found in patients with SSc (5150 vs 8847 pg/mL; P = 0.0001). Fractalkine and galectin-3 levels were significantly higher in diffuse cutaneous SSc than limited cutaneous SSc subset (3.93 ng/mL vs 2.58 ng/mL, P = 0.0018; 6.86 ng/mL vs 3.78 ng/mL, P = 0.0008, respectively) and correlated positively with modified Rodnan Skin Score in total SSc patients (r = 0.376, P = 0.0009; r = 0.236, P = 0.018, respectively). In conclusion, an increased serum level of resistin associated with increased endothelin-1 and fractalkine level and decreased adiponectin level may indicate a significant role of the adipose tissue in the development and progression of vascular abnormalities in patients with systemic sclerosis. Fractalkine and galectin-3 may participate in promoting and exacerbating the fibrotic process in SSc.


2008 ◽  
Vol 35 (12) ◽  
pp. 2363-2371 ◽  
Author(s):  
YASUHITO HAMAGUCHI ◽  
MANABU FUJIMOTO ◽  
TAKASHI MATSUSHITA ◽  
MINORU HASEGAWA ◽  
KAZUHIKO TAKEHARA ◽  
...  

ObjectiveTo examine serum concentrations of insulin-like growth factor (IGF-1) and IGF binding protein (IGFBP-3), a major carrier protein for IGF-1, in patients with systemic sclerosis (SSc); and to relate the results to clinical features in SSc.MethodsSerum IGF-1 and IGFBP-3 levels in 92 Japanese patients with SSc were measured by ELISA. Expression of IGF-1 and IGFBP-3 messenger RNA (mRNA) in the skin was quantified by real-time reverse transcription-polymerase chain reaction.ResultsSerum IGF-1 and IGFBP-3 levels were significantly elevated in patients with SSc compared with patients with systemic lupus erythematosus or healthy controls. IGF-1 levels were higher in patients with diffuse cutaneous SSc (dcSSc) than in patients with limited cutaneous SSc (lcSSc). Patients with increased IGF-1 levels had more severe skin involvement and pulmonary fibrosis. IGF- 1 mRNA was upregulated in the affected skin of patients with SSc. There were no significant differences in serum IGFBP-3 levels between dcSSc and lcSSc. IGFBP-3 levels were not associated with skin thickness and pulmonary fibrosis. Patients with increased IGF-1 or IGFBP-3 had lower frequency of telangiectasia than patients with normal levels.ConclusionThese results suggest that both IGF-1 and IGFBP-3 are involved in the development of SSc. The role of IGF-1 appears to be different from that of IGFBP-3.


Sign in / Sign up

Export Citation Format

Share Document